Source Bioscience Share Discussion Threads

[stevetk] 29/1/2016 21:20

I love his stock. Always positive news, strong business like board (and ruthless). I'm topping up.

[peterz] 29/1/2016 07:49

RNS seems good.

[buywell3] 28/1/2016 23:05

A world first for SBS , and shows what a good acquisition Vindon is proving

I hope to see the next acquisition is a FOOD testing one.

DNA and Bacteria testing











''The only one of its kind in the world, the Source BioScience -70°C walk-in chamber is the first in the new Polar Series and will be welcomed into research and industrial settings alike.''


Sir Ranulph Fiennes to Launch the World’s First -70°C Walk-in Chamber
Back

14 Jan 2016



With temperatures regularly reaching -70°C, the coldest place on earth is unsurprisingly the Antarctic. Source BioScience is now able to replicate these bone-chilling temperatures in an innovative, efficient storage solution.

On the 3rd February, Source BioScience, the international laboratory services and products business, will celebrate the launch of its revolutionary -70°C walk-in chamber, the Polar 50.

The only one of its kind in the world, the Source BioScience -70°C walk-in chamber is the first in the new Polar Series and will be welcomed into research and industrial settings alike. Boasting a high-efficiency insulated enclosure, with an internal volume of 50m3, the chamber is supported with 100% operational redundancy on key components and has been designed for easy installation in any manufacturing or storage facility.

The latest addition to the Company’s growing portfolio of products and services, the first Polar 50 has been installed at the Company’s facility in Rochdale and is available for outsourced storage projects.

Guests attending the launch party will be invited to enjoy an opening speech by CEO, Dr Nick Ash, followed by a presentation by world-famous explorer, Sir Ranulph Fiennes. The Polar 50 will then officially be unveiled by the Mayor and Mayoress of Rochdale, with the cutting of the ribbon.

A champagne reception will give those attending the opportunity to learn more about the Polar 50 and its benefits for clients. During this time, attendees will also be the first to observe the Company’s new analytical chemistry laboratory.

Keith Parkes, Manufacturing Director at Source BioScience, said:

“Engineering equipment which will operate within and maintain a large storage void at -70°C has been a challenging process, requiring close co-ordination between the groups involved in bringing this to fruition. Various operational elements have been built to maintain the low temperature conditions, interface with the key components and fit within our storage facility.

Whilst the project has been extremely challenging, as a team we have delivered a unique engineering solution which will meet the needs of our customers looking to store products at ultra-low temperatures.”

Source BioScience CEO, Dr Nick Ash, said:

“We are delighted to welcome guests to celebrate the launch of this ground-breaking technology, and we are privileged to be hosting a talk by Sir Ranulph Fiennes, the first person to visit the North and South Poles by surface means and cross Antarctica by foot. With his unparalleled experience of the coldest places on Earth, who better to appreciate the impact that our -70°C walk-in chamber could have on research groups involved with Polar studies.”

[peterz] 22/1/2016 10:35

RNS - trust in

[wilkie_hk] 21/1/2016 19:23

Are we expecting a trading statement next week?

[buywell2] 17/1/2016 22:45

Regarding the above


This shows that the area that needs to be improved by the authorities is Pre Clinical trials


The FDA and EMA do not stipulate the use of human living cells from the liver, brain, heart, kidneys and other organs to be used in BOTH in silico AND in vitro Toxicology assays.


It is absolutely disgusting that in 2016 humans become the guinea pigs and as a result die

Politicians need to be held to account










France drug trial: Brain-dead man dies in hospital



A man left brain-dead after an experimental drug trial in France has died, local media report.

He was one of six people being treated in hospital in the city of Rennes.

The hospital said the other five remained in a stable condition - four had "neurological problems" and the fifth had no symptoms.

Reports that the drug was a cannabis-based painkiller have been denied by the French health ministry. The Paris prosecutor has opened an investigation

The trial, which involved taking the drug orally and has now been suspended, was conducted by a private laboratory in Rennes.

Ninety volunteers took the drug, manufactured by the Portuguese company Bial.

Ten of the other 84 have been tested, but did not display any of the "anomalies" of those admitted, the Rennes hospital said in its statement (in French).

On Friday, the chief neuroscientist at the hospital, Gilles Edan, said there was no known antidote to the drug.

Analysis: James Gallagher, health editor, BBC News website

This is the bitter price of the new medicines we take for granted. Testing such experimental drugs, at the cutting edge of science, can never be completely risk-free.

The safety and effectiveness of these drugs are rigorously tested in animals. The risks are low but there must still be a leap of faith when they are tried in people for the first time.

This trial has been taking place since July without such major events being reported. Generally in Phase I trials the dose is increased slowly over time, which could be why the side-effects are appearing now.

The hospitalised men started taking the drug regularly on 7 January and began showing severe side-effects three days later.

It is a high price to pay, but thousands of people do safely take part in similar trials each year.

The trial was conducted by Biotrial, a French-based company with an international reputation which has carried out thousands of trials since it was set up in 1989.

The study was a Phase I clinical trial, in which healthy volunteers take the medication to evaluate the safety of its use, the ministry said.

Before any new medicine can be given to patients, detailed information about how it works and how safe it is must be collected.

Clinical trials are the key to getting that data - and without volunteers to take part in the trials, there would be no new treatments for serious diseases such as cancer, multiple sclerosis and arthritis.

New EU regulations to speed up clinical drug trials and streamline testing procedures across the 28-nation bloc are due to take effect in 2018.
Clinical trials

Trials typically have three phases to assess a new medicine for safety and effectiveness


Phase I tests for safety. A small number of people, sometimes healthy, and sometimes with a medical condition, are given a tiny dose of the drug under careful supervision, not to test if the drug works, but in order to check for any side effects

Phase II sees the drug given to people who have a medical condition to see if it does indeed help them

Phase III trials are only for medicines or devices that have already passed the first two stages, and involve them being compared to existing treatments or a placebo. The trials often last a year or more, involving several thousand patients

[buywell3] 29/12/2015 00:45

The Spartans are driving their chariots onwards

[bartdude] 21/12/2015 08:17

Going up 18p to sell, 18.5 to buy,
are they on someones Christmas list?...

[buywell3] 09/12/2015 21:47

A new superbug found in a gene called MCR-1 has just proved resistant to ALL antibiotics for the FIRST time



Even the last line of defence Colistin has not proved to stop it

This bacterium has been found in chickens sent fro China ( not alive)

The testing that supermarkets will have to do for these bacteria will now grow to MASSIVE proportions.

Companies that do them will make a mint

Source BioScience do not do any

They need to make an acquisition of one that does

[bigman] 05/12/2015 09:03

impressive share performance this year,

[p1nkfish] 02/12/2015 07:39

good news wrt on-line offering expansion.

[buywell3] 29/11/2015 22:08

There should be an update in a couple of weeks I believe

[buywell3] 25/11/2015 22:18

Richard'The Lionheart' Griffiths has sold down

Thanks for your support when it was needed Richard and good luck in your other endeavours

Meantime our second biggest institutional holder has gone to number one spot with circa 24%

SBS should be ready to gobble up another small company early next year after results date perhaps when the share price should I hope and expect be around 20p.

An area I would like to see them get into is doing DNA and bacterial testing on foods ( meat , chicken, fish etc ) for the BIG Supermarkets.

ALL these have been hit hard by previous miss-selling of beef for example with PIG DNA present , Kangeroo DNA in beef burgers ,Chicken with bacterial contamination ... very common

Seems a growth area as the BIG 4 can't lose further ground to Lidl and Aldi

Another meat scandal will do that

[bartdude] 24/11/2015 09:53

Nice to see big investors coming in and bulking up on their share points.

[jamielein] 23/11/2015 16:20

Decided to buy an initial position here today (those were my 15 million shares)...interesting to see a profitable biotech, albeit not rated that cheaply.

P.S. they weren't really my 15 million.

[modform] 23/11/2015 11:41

Bigman, you must be the legendary Chris Mills in disguise

[bigman] 23/11/2015 10:10

modform..... Glad to read you rate me "one of the best" !!! :)

[modform] 20/11/2015 09:41

I added some more this morning after one of the best fund managers has added. why have you gone from buywell2 to buywell3

[buywell3] 19/11/2015 21:44

The 2 Biggest Institutions have been adding

Plus a new Institution enters the fray with 5% stake